160 related articles for article (PubMed ID: 10749583)
21. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of myelodysplastic syndromes and normal bone marrow biopsies with conventional staining and immunocytochemistry.
Das R; Hayer J; Dey P; Garewal G
Anal Quant Cytol Histol; 2005 Jun; 27(3):152-6. PubMed ID: 16121636
[TBL] [Abstract][Full Text] [Related]
24. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
Zhang Z; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
[TBL] [Abstract][Full Text] [Related]
25. [Angiogenesis in bone marrow of myelodysplastic syndrome patients].
Madry K; Dwilewicz-Trojaczek J; Suleiman W; Paszkowska-Kowalewska M; Ziarkiewicz-Wróblewska B
Pol Arch Med Wewn; 2007 Apr; 117(4):25-30. PubMed ID: 17722472
[TBL] [Abstract][Full Text] [Related]
26. Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.
Lorenzo F; Nishii K; Monma F; Kuwagata S; Usui E; Shiku H
Leuk Res; 2006 Oct; 30(10):1235-9. PubMed ID: 16533529
[TBL] [Abstract][Full Text] [Related]
27. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations.
Russell M; List A; Greenberg P; Woodward S; Glinsmann B; Parganas E; Ihle J; Taetle R
Blood; 1994 Aug; 84(4):1243-8. PubMed ID: 8049440
[TBL] [Abstract][Full Text] [Related]
28. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.
Suciu S; Kuse R; Weh HJ; Hossfeld DK
Cancer Genet Cytogenet; 1990 Jan; 44(1):15-26. PubMed ID: 2293879
[TBL] [Abstract][Full Text] [Related]
29. The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes.
Allampallam K; Dutt D; Nair C; Shetty V; Mundle S; Lisak L; Andrews C; Ahmed B; Mazzone L; Zorat F; Borok R; Muzammil M; Gundroo A; Ansaarie I; Raza A
J Hematother Stem Cell Res; 2000 Apr; 9(2):247-55. PubMed ID: 10813538
[TBL] [Abstract][Full Text] [Related]
30. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation.
Tien HF; Tang JH; Tsay W; Liu MC; Lee FY; Wang CH; Chen YC; Shen MC
Br J Haematol; 2001 Jan; 112(1):148-54. PubMed ID: 11167795
[TBL] [Abstract][Full Text] [Related]
31. Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes.
Zwierzina H; Anderson JE; Rollinger-Holzinger I; Torok-Storb B; Nuessler V; Lyman SD
Leukemia; 1999 Apr; 13(4):553-7. PubMed ID: 10214861
[TBL] [Abstract][Full Text] [Related]
32. Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes.
Hofmann WK; Takeuchi S; Xie D; Miller CW; Hoelzer D; Koeffler HP
Leuk Res; 2001 Oct; 25(10):855-8. PubMed ID: 11532517
[TBL] [Abstract][Full Text] [Related]
33. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
[TBL] [Abstract][Full Text] [Related]
35. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
[TBL] [Abstract][Full Text] [Related]
36. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
37. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis.
Zang DY; Goodwin RG; Loken MR; Bryant E; Deeg HJ
Blood; 2001 Nov; 98(10):3058-65. PubMed ID: 11698291
[TBL] [Abstract][Full Text] [Related]
38. Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.
Mangi MH; Mufti GJ
Blood; 1992 Jan; 79(1):198-205. PubMed ID: 1370203
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.
Zhang Z; Li X; Guo J; Xu F; He Q; Zhao Y; Yang Y; Gu S; Zhang Y; Wu L; Chang C
Eur J Haematol; 2013 May; 90(5):375-84. PubMed ID: 23331180
[TBL] [Abstract][Full Text] [Related]
40. Detection of soluble IL-2 receptor in the serum of patients with myelodysplastic syndromes: induction under therapy with GM-CSF.
Zwierzina H; Herold M; Schöllenberger S; Geissler D; Schmalzl F
Br J Haematol; 1991 Nov; 79(3):438-43. PubMed ID: 1751371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
